Differential Dynamics of SARS-CoV-2 Binding and Functional Antibodies upon BNT162b2 Vaccine: A 6-Month Follow-Up.
Adult
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
BNT162 Vaccine
/ administration & dosage
Binding Sites, Antibody
COVID-19
/ immunology
Cohort Studies
Female
Follow-Up Studies
Health Personnel
/ statistics & numerical data
Humans
Immunity, Humoral
Immunoglobulin G
/ blood
Kinetics
Longitudinal Studies
Male
Middle Aged
SARS-CoV-2
/ immunology
Vaccination
SARS-CoV-2
anti-Spike IgG
correlates of protection
humoral response
neutralizing antibodies
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
02 02 2022
02 02 2022
Historique:
received:
13
01
2022
revised:
30
01
2022
accepted:
31
01
2022
entrez:
26
2
2022
pubmed:
27
2
2022
medline:
9
3
2022
Statut:
epublish
Résumé
To investigate the dynamic association among binding and functional antibodies in health-care-workers receiving two doses of BNT162b2 mRNA COVID-19-vaccine, SARS-CoV-2 anti-RBD IgG, anti-Trimeric-S IgG, and neutralizing antibodies (Nabs) were measured in serum samples collected at 2 weeks, 3 months, and 6 months from full vaccination. Despite the high correlation, results for anti-RBD and anti-Trimeric S IgG were numerically different even after recalculation to BAU/mL following WHO standards indications. Moreover, after a peak response at 2 weeks, anti-RBD IgG levels showed a 4.5 and 13 fold decrease at 3 and 6 months, respectively, while the anti-Trimeric S IgG presented a less pronounced decay of 2.8 and 4.7 fold. Further different dynamics were observed for Nabs titers, resulting comparable at 3 and 6 months from vaccination. We also demonstrated that at NAbs titers ≥40, the area under the receiver operating characteristic curve and the optimal cutoff point decreased with time from vaccination for both anti-RBD and anti-Trimeric S IgG. The mutating relation among the anti-RBD IgG, anti-Trimeric S IgG, and neutralizing antibodies are indicative of antibody maturation upon vaccination. The lack of standardized laboratory procedures is one factor interfering with the definition of a correlate of protection from COVID-19.
Identifiants
pubmed: 35215903
pii: v14020312
doi: 10.3390/v14020312
pmc: PMC8878369
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Immunoglobulin G
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministero della Salute
ID : Ricerca Corrente, Linea 1
Organisme : Ministero della Salute
ID : Ricerca Finalizzata COVID-2020-12371817
Organisme : European Union's Horizon 2020 research and innovation programme
ID : 871029-EVA- GLOBAL
Références
Lancet Microbe. 2021 Oct 26;:
pubmed: 34723229
Microbiol Spectr. 2021 Sep 3;9(1):e0024721
pubmed: 34190591
Front Physiol. 2021 Jan 12;11:571416
pubmed: 33510644
Pathogens. 2021 May 07;10(5):
pubmed: 34066983
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Lancet. 2021 Apr 10;397(10282):1347-1348
pubmed: 33770519
Natl Sci Rev. 2021 Mar 27;8(8):nwab053
pubmed: 34676098
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Science. 2022 Feb 11;375(6581):678-680
pubmed: 35040667
Vaccines (Basel). 2021 Jun 18;9(6):
pubmed: 34207300
Viruses. 2021 Apr 10;13(4):
pubmed: 33920222
Lancet. 2021 Apr 3;397(10281):1263-1264
pubmed: 33765410
Vaccines (Basel). 2021 Mar 10;9(3):
pubmed: 33801831
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
J Clin Virol. 2021 Nov;144:104986
pubmed: 34563862
Clin Infect Dis. 2008 Aug 1;47(3):401-9
pubmed: 18558875
Nat Med. 2021 Jul;27(7):1147-1148
pubmed: 34239135
Nat Med. 2022 Jan 20;:
pubmed: 35051990
Clin Chem Lab Med. 2021 Sep 08;59(12):2010-2018
pubmed: 34492749
Science. 2022 Jan 7;375(6576):43-50
pubmed: 34812653
Clin Chem Lab Med. 2021 Nov 23;60(2):e29-e31
pubmed: 34816677
Clin Vaccine Immunol. 2010 Jul;17(7):1055-65
pubmed: 20463105
Mayo Clin Proc. 2020 Oct;95(10):2189-2203
pubmed: 33012349
Front Immunol. 2020 Aug 07;11:1949
pubmed: 32849654
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
Nature. 2021 Nov;599(7883):114-119
pubmed: 34488225
EBioMedicine. 2021 Nov;73:103677
pubmed: 34742128
Vaccines (Basel). 2021 Jun 01;9(6):
pubmed: 34205932
Science. 2021 Sep 17;373(6561):1372-1377
pubmed: 34385356
Clin Chim Acta. 2021 Nov;522:144-151
pubmed: 34425105